

Special Issue

Real-World Clinical Evidence of Novel Antibiotics

Message from the Guest Editors

Several novel antibiotics were developed in the past 10 years to combat multi-drug resistant pathogens. They were approved upon randomized clinical trials (RCT) to demonstrate the efficacy and safety for a specific infection in a controlled environment. On the other hand, real-world evidence (RWE) in the form of post-marketing studies can help to evaluate how the novel antibiotic performs in a diverse population outside of that assessed in RCT. They aim to bridge the gap between clinical trials and routine clinical practice. In this Special Issue, we aim to RWE of antimicrobials in a diverse, challenging patient population that are not commonly represented in RCT such as elderly, non-approved indications, those with augmented renal clearance, as well immunocompromised patients. RWE includes registries, case series, and comparative studies. This fits the scope of antibiotics because it adds to the existing evidence regarding the use of novel antibiotics.

Guest Editors

Dr. Sara Alosaimy

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA

Prof. Dr. Antonio Cascio

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

Deadline for manuscript submissions

closed (15 November 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/114552

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)